Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today announces an abstract has been selected ...

IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) o…

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have been ...

Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on ...

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven ...

Class size headlines miss the reality inside Hillsborough classrooms | Column

Recent coverage of class sizes in Hillsborough County Public Schools raises important questions, but how the data has been ...
TownhallOpinion

AI Data Centers: The New Populist Target

Exploring the political backlash against AI data centers as symbols of economic populism and technological power.

Tubulis to Present Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-resistant Ovarian Cancer in Rapid Oral Presentation at ASCO 2026

Tubulis today announced that an abstract covering current clinical trial data from its ongoing Phase I/IIa NAPISTAR 1-01 trial (NCT06303505) has been accepted for a rapid oral presentation at the ...
TMCnet

Enara Bio Presents First-in-Class DARKFOX-Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential in Solid Tumor ...

Enara Bio, a pioneer in Dark Antigen® discovery and bispecific T cell engager (TCE) innovation, today announced the presentation of new preclinical data for ENA101, its first-in-class bispecific T ...
Opinion
BizPac ReviewOpinion

Ben Shapiro: AI data centers: The new populist target

Op-ed views and opinions expressed are solely those of the author. There’s a growing impulse in American politics to blame the free market — and the technologies […] ...
Opinion
SpaceNewsOpinion

The governance gap: Why orbital data centers need certification before they scale

For more than two decades in sourcing and supply-chain architecture, we’ve watched industries scale only when their supply chains become predictable, certifiable and repeatable. Orbital and lunar data ...

Adcendo ApS Provides Updates on Pipeline Progress and Recent Achievements for Its First- and Best-in-Class Antibody-Drug Conjugates

ADCE-T02, a potential best-in-class Tissue Factor targeted antibody-drug conjugate (ADC), enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors; Two ADC ...

Aulos Bioscience Announces Presentation of Promising Phase 1/2 Data for Imneskibart in Melanoma at 2026 ASCO Annual Meeting

Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today announced that new Phase ...